| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q4 earnings results on Monday, March 11, 2024 at 07:15 AM.
Here's what investors need to know about the announcement.
Lexicon Pharmaceuticals beat estimated earnings by 9.0%, reporting an EPS of $-0.2 versus an estimate of $-0.22.
Revenue was up $674 thousand from the same period last year.
Last quarter the company missed on EPS by $0.0 which was followed by a 9.0% drop in the share price the next day.
Here's a look at Lexicon Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.21 | -0.17 | -0.18 | -0.13 |
| EPS Actual | -0.21 | -0.22 | -0.17 | -0.16 |
| Revenue Estimate | 2.06M | 70K | 30K | 50K |
| Revenue Actual | 162K | 317K | 24K | 28K |
To track all earnings releases for Lexicon Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LXRX
